CYTK
Cytokinetics Inc
64.70$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
Cytokinetics Inc (CYTK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -510 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22 | -31 | -34 | -39 | -47 | -3.0 | -61 | 8.4 | -45 | -46 | -33 | -7.7 | -45 | 4.9 | 37 | -102 | -101 | -91 | 8.9 | -143 | -300 | -414 | -396 | -510 | |
| 2.8 | 3.2 | 3.3 | 3.1 | 2.9 | 2.8 | 2.5 | 2.0 | 1.9 | 1.3 | 0.6 | 0.4 | 0.5 | 0.6 | 0.7 | 1.9 | 1.2 | 1.3 | 1.8 | 2.3 | 5.8 | 12 | 9.5 | 10 | |
| – | – | 1.9 | 1.4 | 4.6 | 4.6 | 5.6 | 4.9 | 4.0 | 3.1 | 3.8 | 3.6 | 3.3 | 4.6 | 7.1 | 9.0 | 9.8 | 11 | 18 | 27 | 48 | 72 | 98 | 112 | |
| – | – | – | – | – | – | – | – | – | 3.3 | 3.7 | 3.5 | 3.3 | 4.5 | 7.7 | 9.0 | 9.8 | 12 | 24 | 34 | 79 | – | – | – | |
| -1.9 | -2.2 | -2.1 | -1.9 | 2.2 | 37 | -14 | -25 | -1.5 | -2.3 | 2.6 | 22 | -34 | 37 | 12 | 0.5 | -23 | -3.9 | 89 | 8.5 | -25 | 3.1 | 36 | -36 | |
| 6.6 | 3.1 | 1.4 | 1.5 | 5.4 | 2.6 | 0.7 | 0.6 | 0.5 | 0.4 | 0.1 | 0.5 | 1.1 | 0.6 | 1.6 | 2.9 | 0.9 | 2.6 | 11 | 49 | 11 | 1.4 | 3.9 | 25 | |
| 23 | -15 | -66 | 34 | -14 | 45 | -10.0 | -53 | 34 | 25 | -29 | -1.5 | -4.0 | 16 | -52 | -66 | 5.1 | -75 | -197 | -148 | -262 | 239 | -553 | 17 | |
| – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | 18 | – | – | |
| 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | 9.3 | 12 | 0.0 | 49 | 9.0 | 1.9 | 126 | 3.2 | 38 | -2.3 | -4.4 | 18 | -11 | 53 | – | |
| – | – | – | – | – | – | – | – | – | -0.8 | -0.2 | – | 15 | 15 | 15 | 1.3 | 9.9 | 1.7 | 335 | 335 | 474 | -0.9 | -9.6 | 316 | |
| 4.9 | 40 | 102 | 5.4 | 87 | 35 | -3.5 | 29 | 2.5 | 22 | 58 | 14 | 49 | 24 | 17 | 226 | 13 | 160 | 234 | 320 | 516 | 221 | 931 | 524 | |
| 5.1 | -5.4 | 2.8 | 0.5 | 26 | 77 | -75 | -16 | -8.0 | 1.3 | -3.9 | 5.3 | 0.1 | 45 | 1.8 | 58 | -83 | -5.8 | 47 | 30 | -45 | 46 | -18 | 30 | |
| -29 | -34 | -35 | -41 | -53 | -5.6 | -62 | 7.9 | -45 | -46 | -34 | -8.3 | -46 | 4.3 | 35 | -105 | -102 | -94 | -2.1 | -191 | -311 | -416 | -400 | -535 |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.